E2 ModerateModerate confidencePEM unclearCase-ControlPeer-reviewedMachine draft
Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.
Tanaka, Susumu, Kuratsune, Hirohiko, Hidaka, Yoh et al. · International journal of molecular medicine · 2003
Quick Summary
This study found that about half of ME/CFS patients have unusual antibodies (immune proteins) that target a specific brain receptor involved in muscle control and nervous system function. Patients with these antibodies reported more muscle weakness and cognitive problems than those without them. This suggests that in some ME/CFS patients, the immune system may be mistakenly attacking the body's own nerve receptors.
Why It Matters
This research provides evidence that autoimmune mechanisms may underlie ME/CFS symptoms in a subset of patients, potentially explaining the neurological and muscular manifestations of the disease. Identifying patients with anti-CHRM1 antibodies could eventually lead to biomarker-based diagnosis and targeted treatments for this autoimmune subgroup.
Observed Findings
- Anti-CHRM1 antibody indices were significantly elevated in 53.3% of ME/CFS patients compared to healthy controls (p<0.0001)
- ME/CFS patients with positive anti-CHRM1 antibodies had significantly higher muscle weakness scores (1.81 vs 1.18, p<0.01)
- Anti-nuclear antibodies were present in 56.7% of ME/CFS patients but showed no correlation with anti-CHRM1, anti-OPRM1, anti-HTR1A, or anti-DRD2 activity
- Anti-OPRM1, anti-HTR1A, and anti-DRD2 antibodies were detected in smaller proportions (15.2%, 1.7%, and 5.0% respectively) of ME/CFS patients
Inferred Conclusions
- Autoantibodies to muscarinic cholinergic receptor 1 represent a distinct immune abnormality in a substantial subgroup of ME/CFS patients
- Anti-CHRM1 antibodies are associated with specific symptoms including muscle weakness, suggesting a potential mechanistic link
- ME/CFS may comprise heterogeneous autoimmune subgroups with different antibody profiles that warrant differential investigation
Remaining Questions
- Are anti-CHRM1 antibodies directly pathogenic, or are they secondary markers of immune dysfunction?
- Do anti-CHRM1 antibody levels change over time or correlate with disease severity and progression?
- How many of the cognitive and pain symptoms in anti-CHRM1-positive patients are directly attributable to receptor autoimmunity versus other concurrent mechanisms?
What This Study Does Not Prove
This study does not prove that anti-CHRM1 antibodies cause ME/CFS symptoms; it only shows association. The cross-sectional design cannot establish temporal relationships or whether antibodies precede symptom onset. It also does not determine whether these antibodies are pathogenic, secondary markers, or incidental findings.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- PMID
- 12851722
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →